LEADER 04593nam 2201357z- 450 001 9910557364503321 005 20231214133313.0 035 $a(CKB)5400000000042247 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/77004 035 $a(EXLCZ)995400000000042247 100 $a20202201d2021 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aKidney Inflammation, Injury and Regeneration 2020 210 $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2021 215 $a1 electronic resource (318 p.) 311 $a3-0365-2370-7 311 $a3-0365-2369-3 330 $aAcute kidney injury (AKI) is still associated with high morbidity and mortality incidence rates, and also bears an elevated risk of chronic kidney disease in the sequel. Whereas the kidney has a remarkable capacity for regeneration after injury and may recover completely depending on the type of renal lesions, the options for clinical intervention are restricted to fluid management and extracorporeal kidney support. The development of novel therapies to prevent AKI, to improve renal regeneration capacity after AKI, and to preserve renal function?in both the short- and long-term?is urgently needed. This Special Issue includes papers investigating the pathological mechanisms of renal inflammation and AKI and diagnostics using new biomarkers. Furthermore, experimental in vitro and in vivo studies examining potential new approaches to attenuate kidney dysfunction are included, as well as review articles. 606 $aMedicine$2bicssc 610 $ainflammation 610 $achronic kidney disease 610 $aanemia 610 $aanemia of inflammation 610 $aESA hyporesponsiveness 610 $arenal tubular epithelial cells 610 $amacrophages 610 $alipocalin-2 610 $airon 610 $acilastatin 610 $ahypoxia inducible factor-1-? 610 $aischemia-reperfusion injury 610 $aacute kidney injury 610 $acyclophilin A 610 $afibrosis 610 $arenal fibrosis 610 $atubular necrosis 610 $apreeclampsia 610 $apodocytes 610 $aVEGF 610 $aFSGS 610 $aproteinuria 610 $aendocan 610 $aESM-1 610 $arenal replacement therapy 610 $akidney transplantation 610 $abiomarker 610 $adiabetic nephropathy 610 $afocal segmental glomerulosclerosis 610 $ainnate immunity 610 $amembranous nephropathy 610 $aminimal change diseases 610 $aTLR 610 $aNOX1 610 $aML171 610 $areactive oxygen species 610 $aERK 610 $aT cells 610 $aglomerulonephritis 610 $achemokines 610 $arenal disease 610 $aDJ-1 610 $aND-13 610 $arenal inflammation 610 $aoxidative stress 610 $aUUO 610 $aautophagy 610 $aapoptosis 610 $atrehalose 610 $asimvastatin 610 $aendotoxin 610 $atubular apoptosis 610 $acytochrome C 610 $aBcl-XL 610 $asurvivin 610 $ahypercholesterolemia 610 $axanthine oxidase 610 $aNF-?B pathway 610 $atertiary lymphoid organs 610 $aB cells 610 $aBAFF 610 $akidney fibrosis 610 $amyofibroblast activation 610 $aextracellular matrix 610 $aHippo pathway 610 $averteporfin 610 $aIgAN 610 $aCKD 610 $aprogression 610 $aACEI 610 $acorticosteroids 610 $acostimulation 610 $acoinhibition 610 $akidney transplant 610 $aSPR 610 $aprotein binding affinity 610 $aadaptive immunity 610 $aepithelial-to-mesenchymal transition 610 $aE. cava extracts 610 $adieckol 610 $aspontaneously hypertensive rats 610 $aangiotensin II 615 7$aMedicine 700 $aBaer$b Patrick C$4edt$01293413 702 $aKoch$b Benjamin$4edt 702 $aGeiger$b Helmut$4edt 702 $aBaer$b Patrick C$4oth 702 $aKoch$b Benjamin$4oth 702 $aGeiger$b Helmut$4oth 906 $aBOOK 912 $a9910557364503321 996 $aKidney Inflammation, Injury and Regeneration 2020$93032035 997 $aUNINA